阮林 朱卓麗 連肖強(qiáng) 黃煥森
【摘要】 目的 觀察丙泊酚對膠質(zhì)瘤細(xì)胞侵襲和轉(zhuǎn)移的影響, 探討內(nèi)質(zhì)網(wǎng)應(yīng)激(ERS)在膠質(zhì)瘤細(xì)胞侵襲和轉(zhuǎn)移的作用機(jī)制。方法 人膠質(zhì)瘤細(xì)胞系U87-MG細(xì)胞培養(yǎng)分為對照組(C組)、2 μg/ml組、5 μg/ml組和10 μg/ml組, 分別加入濃度為0、2、5和10 μg/ml丙泊酚溶液。采用MTT法檢測細(xì)胞活力;Transwell侵襲遷移測定侵襲細(xì)胞數(shù);劃痕實(shí)驗(yàn)測定遷移率;Western blot檢測細(xì)胞葡萄糖調(diào)節(jié)蛋白78(GRP78)和CCAAT/增強(qiáng)子結(jié)合蛋白同源蛋白(CHOP)表達(dá)。比較每組細(xì)胞細(xì)胞活力、侵襲細(xì)胞數(shù)、遷移率及GRP78和CHOP表達(dá)。結(jié)果 2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞活力低于C組, 且隨丙泊酚劑量增加膠質(zhì)瘤細(xì)胞活力及遷移率逐漸降低, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞侵襲細(xì)胞數(shù)少于C組, 2 μg/ml組膠質(zhì)瘤細(xì)胞侵襲細(xì)胞數(shù)多于5、10 μg/ml組, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。
C組與5、10 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。2 μg/ml組與5、10 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。5 μg/ml組與10 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。C組與2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞CHOP表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。10 μg/ml組與2、5 μg/ml組膠質(zhì)瘤細(xì)胞CHOP表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 丙泊酚可抑制人膠質(zhì)瘤細(xì)胞的侵襲和遷移能力, 其機(jī)制可能與激活內(nèi)質(zhì)網(wǎng)應(yīng)激標(biāo)志蛋白GRP78和CHOP表達(dá)變化有關(guān)。
【關(guān)鍵詞】 丙泊酚;膠質(zhì)瘤細(xì)胞;內(nèi)質(zhì)網(wǎng)應(yīng)激
DOI:10.14163/j.cnki.11-5547/r.2019.31.105
Endoplasmic reticulum stress mechanism of propofol inhibiting invasion and metastasis of glioma cells ? RUAN Lin, ZHU Zhuo-li, LIAN Xiao-qiang, et al. Department of Anesthesia, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
【Abstract】 Objective ? To observe the effect of propofol on invasion and metastasis of glioma cells, and discuss the mechanism of endoplasmic reticulum stress (ERS) in invasion and metastasis of glioma cells. Methods ?Human glioma cell line U87-MG was divided into control group (group C), 2 μg/ml group, 5 μg/ml group and?10 μg/ml group, and propofol solution was added at concentrations of 0, 2, 5 and 10 μg/ml, respectively. Cell viability was detected by MTT assay, number of invasive cell by Transwell invasion and migration assay, migration rate by scratch assay, and expression of cell glucose regulatory protein 78 (GRP78) and CCAAT / enhancer binding protein homologous protein (CHOP) by Western blot. Cell viability, number of invasive cell, migration rate and expression of GRP78 and CHOP were compared in each group. Results ?The cell viability of glioma cells in 2, 5 and 10 μg/ml group was lower than that in group C, and the cell viability and migration rate of glioma cells decreased with the increase of propofol dosage, the difference was statistically significant (P<0.05). The number of invasive cell of glioma cells in 2, 5 and 10 μg/ml group was lower than that in group C, and 2 μg/ml group was more than 5 and 10 μg/ml group. Their difference was statistically significant (P<0.05). There was statistically significant difference in expression of GRP78 of glioma cells in group C and 5 and 10 μg/ml group (P<0.05). 2 μg/ml?group and 5 and 10 μg/ml group had statistically significant difference in expression of GRP78 of glioma cells (P<0.05). 5 μg/ml group and 10 μg/ml group had statistically significant difference in expression of GRP78 of glioma cells (P<0.05). Group C and 2, 5 and 10 μg/ml group had statistically significant difference in expression of CHOP of glioma cells (P<0.05). 10 μg/ml group and 2, 5 μg/ml group had statistically significant difference in expression of GRP78 of glioma cells (P<0.05). Conclusion ? Propofol inhibits the invasion and migration of human glioma cells, and its mechanism may be related to the activation of endoplasmic reticulum stress marker proteins GRP78 and CHOP.
【Key words】 Propofol; Glioma cells; Endoplasmic reticulum stress
膠質(zhì)瘤是中樞神經(jīng)系統(tǒng)最常見的原發(fā)腫瘤, 膠質(zhì)瘤細(xì)胞的高度增殖性和侵襲性是其主要的病理特征, 是預(yù)后不良的主要原因[1]。丙泊酚化學(xué)名為2, 6-二異丙基苯酚, 是一種靜脈麻醉藥物, 常用于全身麻醉的誘導(dǎo)和維持, 特點(diǎn)是起效快, 持續(xù)時(shí)間短, 蘇醒迅速而平穩(wěn), 不良反應(yīng)少, 廣泛應(yīng)用于各種外科手術(shù)中。研究發(fā)現(xiàn)丙泊酚在許多腫瘤, 如肺癌、胃癌和結(jié)腸癌等中有抗腫瘤的作用[2]。內(nèi)質(zhì)網(wǎng)應(yīng)激(endoplasmic reticulum stress, ERS)促腫瘤侵襲是腫瘤調(diào)控的新機(jī)制[3]。
1 材料與方法
1. 1 細(xì)胞培養(yǎng) 人膠質(zhì)瘤細(xì)胞系U87-MG細(xì)胞常規(guī)培養(yǎng)。在10%胎牛血清含青霉素(100 U/ml)和鏈霉素(100 mg/L)的1640培養(yǎng)基中, 37℃、5%CO2、飽和濕度條件下培養(yǎng)。
1. 2 實(shí)驗(yàn)分組 人膠質(zhì)瘤細(xì)胞系U87-MG細(xì)胞培養(yǎng)分為4組(n=24):對照組(C組)、2 μg/ml組、5 μg/ml組和10 μg/ml組, 分別加入濃度為0、2、5和10 μg/ml丙泊酚溶液, 孵育6 h后換培養(yǎng)液, 繼續(xù)培養(yǎng)18 h。
1. 3 MTT法測定 人膠質(zhì)瘤細(xì)胞系U87-MG細(xì)胞密度為5×104/ml, 接種于96孔板中, 每孔200 μl。各組取6孔, 每孔加入含MTT濃度為5 mg/ml的PBS 20 μ1, 培養(yǎng)4 h待甲躦結(jié)晶形成后加入二甲基亞砜150 μl, 置于酶標(biāo)儀570 nm波長下測定吸光度值, 反映細(xì)胞活力。
1. 4 Transwell侵襲遷移測定 細(xì)胞侵襲與遷移能力測定采用24孔Transwell小室和Matrigel(B&D公司)。細(xì)胞培養(yǎng)至80%融合時(shí), 收集細(xì)胞, 調(diào)整細(xì)胞數(shù)為5×105/ml;Transwell下室中加入600 μl含丙泊酚處理 RPMI 1640培養(yǎng)液孵育40 h。0.1%結(jié)晶紫染色15 min, 每個(gè)濾膜隨機(jī)在顯微鏡下選取8個(gè)高倍視野(×200), 計(jì)數(shù)穿過聚碳酯膜的細(xì)胞。
1. 5 細(xì)胞劃痕實(shí)驗(yàn) 細(xì)胞接種6孔板至細(xì)胞80%融合, 各組取6孔, 用20 μl無菌槍頭做垂直于孔板長緣的均勻劃痕。以100倍視野攝片并標(biāo)記攝片位置(T0), 培養(yǎng)24 h在相同位置再次攝片(T1)。用Image Pro Plus軟件拍攝照片的劃痕距離, 計(jì)算細(xì)胞遷移率=(T0距離-T1距離)/T0距離×100%。
1. 6 Western blot檢測 細(xì)胞加入蛋白裂解液及PMSF, 超聲破碎, 4℃、12000 r/min離心40 min, 取上清。用Bradford法對上清做蛋白定量。取20 μg蛋白作10% SDS-PAGE電泳, 100 V轉(zhuǎn)移1 h至PVDF膜, 葡萄糖調(diào)節(jié)蛋白78(glucose regulated protein78, GRP78)和CCAAT/增強(qiáng)子結(jié)合蛋白同源蛋白(CCAAT/enhancer-binding protein homologous protein, CHOP) 4℃過夜。將膜與辣根過氧化物酶(HRP)標(biāo)記的抗IgG抗體孵育, 用ECL化學(xué)發(fā)光試劑觀察條帶。用不含抗體TBST液孵育作陰性對照。圖像分析測定各帶作定量分析, 以目的蛋白與內(nèi)參蛋白灰度值的比值反映蛋白的表達(dá)。
1. 7 統(tǒng)計(jì)學(xué)方法 采用SPSS19.0統(tǒng)計(jì)學(xué)軟件處理數(shù)據(jù)。計(jì)量資料以均數(shù)±標(biāo)準(zhǔn)差( x-±s)表示, 采用t檢驗(yàn);計(jì)數(shù)資料以率(%)表示, 采用χ2檢驗(yàn)。P<0.05表示差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞活力低于C組, 且隨丙泊酚劑量增加膠質(zhì)瘤細(xì)胞活力逐漸降低, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞侵襲細(xì)胞數(shù)少于C組, 2 μg/ml組膠質(zhì)瘤細(xì)胞侵襲細(xì)胞數(shù)多于5、10 μg/ml組, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。而5和10 μg/ml P組侵襲細(xì)胞數(shù)比較, 差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞遷移率低于C組, 且隨丙泊酚劑量增加膠質(zhì)瘤細(xì)胞遷移率逐漸降低, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。C組與2 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。
C組與5、10 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。2 μg/ml組與5、10 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。5 μg/ml組與10 μg/ml組膠質(zhì)瘤細(xì)胞GRP78表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。C組與2、5和10 μg/ml組膠質(zhì)瘤細(xì)胞CHOP表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。10 μg/ml組與2、5 μg/ml組膠質(zhì)瘤細(xì)胞CHOP表達(dá)比較, 差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。2 μg/ml組與5 μg/ml組膠質(zhì)瘤細(xì)胞CHOP表達(dá)比較, 差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。見表1。
3 討論
丙泊酚在體外實(shí)驗(yàn)中抑制HeLa細(xì)胞株、HT1080細(xì)胞株、黑色素瘤細(xì)胞株的侵襲, 在小鼠骨肉瘤模型中丙泊酚可降低小鼠骨肉瘤細(xì)胞株LM8的肺轉(zhuǎn)移[4]。丙泊酚作用于人乳腺癌細(xì)胞, 抑制核因子κB(nuclear factor kappa-B, NF-κB)信號途徑, 從而抑制乳腺癌細(xì)胞的侵襲和遷移[5]。小劑量丙泊酚能夠促進(jìn)食管鱗癌細(xì)胞Ecal09的增殖、遷移與侵襲并抑制凋亡[6]。丙泊酚對腫瘤生物學(xué)行為影響的研究尚存在爭議。
GRP78是熱休克蛋白70(HSP70)家族成員之一, 在成熟組織中表達(dá)量很低, 但ERS時(shí)可大量產(chǎn)生, 與腫瘤細(xì)胞的侵襲轉(zhuǎn)移、耐藥等密切相關(guān)[7]。CHOP屬于C/EBP家族成員之一, 參與ERS介導(dǎo)細(xì)胞凋亡的特有途徑[8]。本實(shí)驗(yàn)采用人膠質(zhì)瘤細(xì)胞進(jìn)行研究, 以不同劑量濃度丙泊酚處理膠質(zhì)瘤細(xì)胞活力、侵襲細(xì)胞數(shù)、遷移率下降, GRP78和CHOP表達(dá)下調(diào)。
綜上所述, 丙泊酚可抑制人膠質(zhì)瘤細(xì)胞的侵襲和遷移能力有一定抑制作用, 其機(jī)制與ERS有關(guān), 為丙泊酚在膠質(zhì)瘤圍術(shù)期應(yīng)用提供理論基礎(chǔ)。
參考文獻(xiàn)
[1] Carabenciov ID, Buckner JC. Controversies in the therapy of low-grade gliomas. Curr Treat Options Oncol, 2019, 20(4):25.
[2] Sun H, Gao D. Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372. BMC Cancer, 2018, 18(1):1252.
[3] Grootjans J, Krupka N, Hosomi S, et al. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. Science, 201, 363(6430):993-998.
[4] Mammoto T, Mukai M, Mammoto A, et al. Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett, 2002, 184(2):165-170.
[5] Li Q, Zhang L, Han Y, et al. Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells. Biomed Pharmacother, 2012, 66(1):52-56.
[6] 張靈敏, 張明鑫, 王寧, 等. 小劑量丙泊酚對食管鱗癌細(xì)胞Ecal09生物學(xué)行為的影響. 細(xì)胞與分子免疫學(xué)雜志, 2011, 27(4):402-404.
[7] Bailly C, Waring MJ. Pharmacological effectors of GRP78 chaperone in cancers. Biochem Pharmacol, 2019(163):269-278.
[8] Wang Y, Wang K, Jin Y, et al. Endoplasmic reticulum proteostasis control and gastric cancer. Cancer Lett, 2019(449):263-271.
[收稿日期:2019-03-20]